Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.32 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.30 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25760261 | 0.92 | THRB (0.34) | HTTALKBH3MEN1KMT2A | |
| SCHEMBL21751382 | 0.92 | CASR (0.34) | ALDH1A1 | |
| SCHEMBL21751407 | 0.87 | MAOA (0.34) | ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL21751307 | 0.87 | LTB4R (0.31) | LTB4R | |
| SCHEMBL492636 | 0.86 | LTB4R (0.41) | KDM4EALDH1A1GAAHPGDHTT | |
| SCHEMBL21751334 | 0.85 | GNRHR (0.32) | ALDH1A1KMT2A | |
| SCHEMBL25760435 | 0.85 | ALKBH3 (0.30) | ALKBH3 | |
| SCHEMBL19206668 | 0.85 | NPY5R (0.38) | KDM4EALDH1A1GAAHPGDHTT | |
| SCHEMBL20543762 | 0.85 | ADORA3 (0.34) | KDM4EALDH1A1GAAHPGDHTT | |
| SCHEMBL21948642 | 0.84 | ADORA3 (0.35) | KDM4EALDH1A1GAAHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340923-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORP (US) | 2025-11-06 | — | — | US | claimed |
| US-20240197923-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | INSTITUT PASTEUR (FR) | 2024-06-20 | — | — | US | claimed |
| EP-3964501-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | INSTITUT PASTEUR (FR) | 2022-03-09 | — | — | EP | claimed |
| US-20210254128-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2021-08-19 | — | — | US | claimed |
| US-11015216-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2021-05-25 | — | — | US | claimed |
| US-20200263229-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2020-08-20 | — | — | US | claimed |
| US-10669568-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2020-06-02 | — | — | US | claimed |
| US-20200129644-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | INSTITUT PASTEUR (FR) | 2020-04-30 | — | — | US | claimed |
| US-20190241932-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2019-08-08 | — | — | US | claimed |
| EP-3416968-A1 | COELENTERAZINE ANALOGUES | Promega Corporation (US) | 2018-12-26 | — | — | EP | claimed |
| EP-3395803-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | Institut Pasteur (FR) | 2018-10-31 | — | — | EP | claimed |
| US-20180223330-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2018-08-09 | — | — | US | claimed |
| WO-2017142852-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION (US) | 2017-08-24 | — | — | WO | claimed |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-08-17 | — | — | US | claimed |
| US-12612411-B1 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2026-04-28 | — | — | US | disclosed |
| US-12576164-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | INSTITUT PASTEUR (FR) | 2026-03-17 | — | — | US | disclosed |
| US-20250340923-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-9924073-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates and preparation method thereof | PROMEGA CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
| WO-2017142852-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION (US) | 2017-08-24 | — | — | WO | disclosed |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200129644-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | NISCH, HLCS, CYP3A5 | KDM4E 2228/4885ALDH1A1 972/4885GAA 2507/4885 |
| US-12576164-B2 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | LUC7L2, HLCS, LANCL1 | KDM4E 3911/4885ALDH1A1 659/4885GAA 1912/4885 |
| US-20210254128-A1 | COELENTERAZINE ANALOGUES | AADAC, GLB1, PGLS | KDM4E 3757/4885ALDH1A1 2295/4885GAA 925/4885 |
| US-20250340923-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PGLS, AADAC, GLB1 | KDM4E 4319/4885ALDH1A1 1179/4885GAA 1024/4885 |
| US-20190241932-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | KDM4E 3302/4885ALDH1A1 3541/4885GAA 188/4885 |
| US-11015216-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | GLB1, PGLS, AADAC | KDM4E 4242/4885ALDH1A1 529/4885GAA 862/4885 |
| US-20180223330-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | KDM4E 3302/4885ALDH1A1 3541/4885GAA 188/4885 |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | KDM4E 3302/4885ALDH1A1 3541/4885GAA 188/4885 |
| US-12612411-B1 | Imidazopyrazine derivatives, process for preparation thereof, and their uses as luciferins | LUC7L2, MRPL21, CRY1 | KDM4E 3245/4885ALDH1A1 1484/4885GAA 4623/4885 |
| US-20200263229-A1 | COELENTERAZINE ANALOGUES | AADAC, GLB1, PGLS | KDM4E 3757/4885ALDH1A1 2295/4885GAA 925/4885 |
| US-20240197923-A1 | IMIDAZOPYRAZINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF, AND THEIR USES AS LUCIFERINS | NISCH, HLCS, CYP3A5 | KDM4E 2228/4885ALDH1A1 972/4885GAA 2507/4885 |
| US-10669568-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | AADAC, PGLS, GLB1 | KDM4E 4304/4885ALDH1A1 1148/4885GAA 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.